Company Info
Phone(780) 818-6422
Year Established
2017
Ticker
BNXT
Exchange
CSE
Contacts
Hugh RogersCEO
Company Description
BioNxt is developing a 100% owned and proprietary hybrid-generic ODF Cladribine dosage form, directed at the multiple sclerosis ('MS') market.